Inactive Ingredient Search for Approved Drug Products

About this Database | Back to Search Page

Guidances | CFR

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with S

	Quarter	Inactive Ingredient	Route of Administration	Dosage Form	Maximum Potency per unit dose	Maximum Daily Exposure	Status
264927	Q3 2023	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	TOPICAL	SOLUTION	0.47 %w/v		Deletion
264928	Q3 2023	SORBITOL	ORAL	SUSPENSION/ DROPS	30.00 mg/ 1.00 ml		Deletion
264929	Q3 2023	SORBITOL	TOPICAL	SOLUTION/ DROPS	6.90 %w/v		Deletion
265062	Q2 2023	SODIUM BENZOATE	TOPICAL	GEL	0.24 %w/w		MDE Replacement
265063	Q3 2023	SODIUM BENZOATE	TOPICAL	GEL		5mg	MDE Replacement
265064	Q2 2023	SODIUM BICARBONATE	ORAL	GUM, CHEWING	15.00 mg		MDE Replacement
265065	Q3 2023	SODIUM BICARBONATE	ORAL	GUM, CHEWING		360mg	MDE Replacement
265066	Q2 2023	SODIUM CARBONATE	ORAL	GUM, CHEWING	10.00 mg		MDE Replacement
265067	Q3 2023	SODIUM CARBONATE	ORAL	GUM, CHEWING		240mg	MDE Replacement
265068	Q2 2023	SODIUM CHLORIDE	INTRA-ARTERIAL	INJECTION, SOLUTION	0.01 %w/v		MDE Replacement
265069	Q3 2023	SODIUM CHLORIDE	INTRA-ARTERIAL	INJECTION, SOLUTION		278mg	MDE Replacement
265070	Q2 2023	SODIUM HYDROXIDE	VAGINAL	GEL	0.25 %w/w		MDE Replacement
265071	Q3 2023	SODIUM HYDROXIDE	VAGINAL	GEL		20mg	MDE Replacement
265072	Q2 2023	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	INTRALESIONAL	INJECTION, SUSPENSION	0.14 %w/v		MDE Replacement
265073	Q3 2023	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	INTRALESIONAL	INJECTION, SUSPENSION		3mg	MDE Replacement
265074	Q2 2023	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	SOFT TISSUE	INJECTION, SUSPENSION	0.14 %w/v		MDE Replacement
265075	Q3 2023	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	SOFT TISSUE	INJECTION, SUSPENSION		3mg	MDE Replacement
265076	Q2 2023	SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE	OPHTHALMIC	SOLUTION	1.26 %w/v		MDE Replacement
265077	Q3 2023	SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE	OPHTHALMIC	SOLUTION		5mg	MDE Replacement
265078	Q2 2023	SODIUM PROPIONATE	ORAL	SYRUP	10.00 mg/ 5.00 ml		MDE Replacement
265079	Q3 2023	SODIUM PROPIONATE	ORAL	SYRUP		40mg	MDE Replacement
265080	Q2 2023	SORBIC ACID	ORAL	SOLUTION	5.00 mg/ 5.00 ml		MDE Replacement
265081	Q3 2023	SORBIC ACID	ORAL	SOLUTION		80mg	MDE Replacement
265082	Q2 2023	SORBITAN MONOOLEATE	ORAL	TABLET, DELAYED RELEASE	1.89 mg		MDE Replacement
265083	Q3 2023	SORBITAN MONOOLEATE	ORAL	TABLET, DELAYED RELEASE		4mg	MDE Replacement
265084	Q2 2023	SORBITOL	ORAL	GUM, CHEWING	257.00 mg		MDE Replacement
265085	Q3 2023	SORBITOL	ORAL	GUM, CHEWING		6168mg	MDE Replacement
265086	Q2 2023	STARCH 826	ORAL	TABLET	138.00 mg		MDE Replacement
265087	Q3 2023	STARCH 826	ORAL	TABLET		320mg	MDE Replacement
265088	Q2 2023	STARCH, PREGELATINIZED	ORAL	TABLET, COATED	125.00 mg		MDE Replacement
265089	Q3 2023	STARCH, PREGELATINIZED	ORAL	TABLET, COATED		460mg	MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: July 6, 2023
Database Last Updated: July 21, 2023